Clear All
12482 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00002-5340-60 00002-5340 Selpercatinib RETEVMO 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral Apr 10, 2024 In Use
70709-0192-12 70709-0192 Nilotinib CAVHANZA 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 30, 2026 In Use
70709-0191-12 70709-0191 Nilotinib CAVHANZA 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 30, 2026 In Use
00597-0138-95 00597-0138 Afatinib Gilotrif 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 8, 2013 Apr 30, 2027 In Use
72603-0923-01 72603-0923 DASATINIB DASATINIB 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 1, 2026 In Use
72485-0217-30 72485-0217 Erlotinib hydrochloride Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov 6, 2019 In Use
72603-0922-01 72603-0922 DASATINIB DASATINIB 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 1, 2026 In Use
43598-0458-04 43598-0458 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET, CRAF, BRAF Oral Jun 8, 2022 In Use
43598-0046-28 43598-0046 SUNITINIB MALATE SUNITINIB MALATE 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Nov 30, 2022 In Use
72603-0924-01 72603-0924 DASATINIB DASATINIB 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 1, 2026 In Use
59651-0466-29 59651-0466 SUNITINIB MALATE SUNITINIB MALATE 37.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Mar 14, 2024 In Use
72603-0925-01 72603-0925 DASATINIB DASATINIB 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 1, 2026 In Use
85001-0101-01 85001-0101 Zidesamtinib JIDEYTRO 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, ALK, TRK Oral Jul 22, 2026 In Use
72603-0926-01 72603-0926 DASATINIB DASATINIB 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 1, 2026 In Use
00069-0197-30 00069-0197 Dacomitinib Vizimpro 15.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct 4, 2018 Dec 31, 2029 In Use
50242-0092-01 50242-0092 ENTRECTINIB Rozlytrek 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRKA, TRKB, TRKC, ROS1, ALK Oral Aug 15, 2019 No Longer Used
16714-0677-01 16714-0677 Sunitinib malate Sunitinib malate 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Feb 18, 2022 Sep 30, 2026 In Use
64842-0127-07 64842-0127 FUTIBATINIB LYTGOBI 16.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral Jun 1, 2026 In Use
00173-0804-09 00173-0804 Pazopanib Hydrochloride Votrient 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, Lck, FMS Oral Oct 19, 2009 Jun 30, 2017 No Longer Used
00069-2299-30 00069-2299 Dacomitinib Vizimpro 45.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct 4, 2018 Oct 31, 2028 In Use
85001-0102-01 85001-0102 Zidesamtinib JIDEYTRO 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, ALK, TRK Oral Jul 22, 2026 In Use
00069-0227-01 00069-0227 Lorlatinib Lorbrena 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1 Oral Nov 19, 2018 In Use
72603-0927-01 72603-0927 DASATINIB DASATINIB 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 1, 2026 In Use
00069-0227-03 00069-0227 Lorlatinib Lorbrena 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1 Oral Jan 3, 2025 Mar 31, 2027 In Use
60505-3802-07 60505-3802 Nilotinib Nilotinib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 25, 2025 In Use

Found 12482 results — Export these results